We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
Beneficial Effect of Early Intervention with Garenoxacin for Bacterial Infection-Induced Acute Exacerbation of Bronchial Asthma and Chronic Obstructive Pulmonary Disease.
- Authors
Homma, Tetsuya; Kawahara, Tomoko; Mikuni, Hatsuko; Uno, Tomoki; Sato, Haruna; Fujiwara, Akiko; Uchida, Yoshitaka; Fukuda, Yosuke; Manabe, Ryo; Ida, Hitomi; Kuwahara, Naota; Kimura, Tomoyuki; Hirai, Kuniaki; Miyata, Yoshito; Jinno, Megumi; Yamaguchi, Munehiro; Kishino, Yasunari; Murata, Yasunori; Ohta, Shin; Yamamoto, Mayumi
- Abstract
>bold<>italic<Background:>/italic<>/bold< Chronic obstructive pulmonary disease (COPD) and asthma have similar clinical features and are both exacerbated by airway infection. >bold<>italic<Objective:>/italic<>/bold< To determine whether garenoxacin mesylate hydrate (GRNX) added to the standard care for bacterial infection-induced acute exacerbation of asthma or COPD in adults has clinical benefits. >bold<>italic<Method:>/italic<>/bold< This single-arm clinical trial was conducted from January 2015 to March 2016. Adults with a history of asthma or COPD for more than 12 months were recruited within 48 h of presentation with fever and acute deterioration of asthma or COPD requiring additional intervention. Participants were administered 400 mg GRNX daily for 7 days without additional systemic corticosteroids or other antibiotics. The primary outcome was efficacy of GRNX based on clinical symptoms and blood test results after 7 days of treatment. Secondary outcomes were: (1) comparison of the blood test results, radiograph findings, and bacterial culture surveillance before and after treatment; (2) effectiveness of GRNX after 3 days of administration; (3) analyzation of patient symptoms based on patient diary; and (4) continued effectiveness of GRNX on 14th day after the treatment (visit 3). >bold<>italic<Results:>/italic<>/bold< The study included 44 febrile patients (34 asthma and 10 COPD). Frequently isolated bacteria included >italic<Moraxella catarrhalis>/italic< (>italic<n>/italic< = 6) and >italic<Klebsiella pneumoniae>/italic< (>italic<n>/italic< = 4). On visit 2, 40 patients responded, and no severe adverse events were observed. All secondary outcomes showed favorable results. >bold<>italic<Conclusion:>/italic<>/bold< GRNX effectively treated asthma and COPD patients with acute bacterial infection without severe adverse events. Further research with a larger study population is needed.
- Subjects
OBSTRUCTIVE lung diseases; ASTHMA
- Publication
International Archives of Allergy & Immunology, 2019, Vol 178, Issue 4, p355
- ISSN
1018-2438
- Publication type
Article
- DOI
10.1159/000495761